Circulating miRNAs.

Launched by CANCER TRIALS IRELAND · Nov 5, 2012

Keywords

ClinConnect Summary

Primary Objectives:

1. To identify a panel of miRNAs, detectable in the circulation, which are altered in breast cancer patients
2. To identify specific combinations of miRNAs ('signatures') which associate with breast cancer intrinsic subtypes, and thereby could aid in prognostication and treatment planning on an individual patient basis.

Secondary Objective:

1. To determine if systemic miRNA analysis can be used as a biomarker for monitoring response to chemotherapy, in the neoadjuvant setting and in patients who present with breast cancer recurrence and are treated with upfront chemot...

Gender

FEMALE

Eligibility criteria

• • Inclusion Criteria
• 1. Patient must meet the criteria for either:
• • Cohort 1: All patients with a new diagnosis of breast cancer, who are destined to undergo neoadjuvant chemotherapy.
• • OR Cohort 2: All breast cancer patients who present with metastatic disease, disease recurrence or progression who will receive up-front chemotherapy ± hormonal therapy.
• • OR Cohort 3: All breast cancer patient who present with metastatic disease who are commencing hormonal therapy only.
• • 2. Patients must be aged 18 years or over.
• • 3. Patients must be able to give written informed consent.
• • Exclusion Criteria
• • All patients, who do not fulfil the inclusion criteria mentioned above.